New study results for Tikomed’s platform lead drug candidate ILB in the treatment of patients with amyotrophic lateral sclerosis (ALS), have been published in the Journal of Personalized Medicine.
The data reveals a significant normalization of the serum levels of several key metabolites in addition to a significant improvement of patients’ clinical conditions for the duration of the ILB treatment period. The treatment response appears to be mediated by improvement of tissue bioenergetics, decrease of oxidative/nitrosative stress and attenuation of (neuro)inflammatory processes.
The deranged neuronal function associated with the oxidative/nitrosative stress and mitochondrial dysfunction characterized by the pathophysiological progress of neurodegenerative conditions such as ALS is reflected by changes in related metabolites in blood. When measured, these metabolites can be used as biomarkers of tissue function and, therefore, of disease progression and/or patient response to treatment.
In this study of a cohort of patients with ALS who had participated in the clinical trial, repeated ILB administration over 4 weeks led to a significant attenuation of the levels of key serum metabolites related to neural damage, oxidative/nitrosative stress and mitochondrial derangement, a media release from Tikomed explains.
“We are very pleased that these results strongly suggest that ILB treatment produces metabolic benefits corresponding with the encouraging clinical improvements seen for the ALS patients participating in this study.
“The adaptive, multi modal mechanism of action of ILB and the growing scientific evidence supporting its ability to rebalance the body’s own inflammatory response and enhance endogenous repair mechanisms gives us the limitless potential to pursue all disease areas driven by uncontrolled or dysfunctional inflammation, on our quest to provide safe and affordable medicines to as many patients as possible across the globe.”
— Anders Kristensson, CEO of Tikomed
[Source(s): Tikomed, PR Newswire]